Immune checkpoint pathways involve both costimulatory and inhibitory proteins. The costimulatory receptors transduce signals to promote immunity against pathogens, whereas the co-inhibitory receptors negatively regulate T-cell activation to prevent self-immunity in normal tissues. Tumor cells can hijack the checkpoint pathways by upregulating the inhibitory checkpoint proteins to avoid attacks from the immune system. Blocking the inhibitory pathways could thus restore the immune system against cancers. Recently, anti-CTLA4 and anti-PD1 monoclonal antibodies have demonstrated anti-tumor effect in patients with a variety of malignancies, and several products have been approved for cancer treatment. Encouraged by this early success, researchers have expanded their investigations into other checkpoint proteins in order to find better ways to treat cancer.
G-Biosciences offers a comprehensive collection of >90 immune checkpoint proteins. These products have demonstrated consistent and excellent performance in a variety of assays. In addition to human proteins, we also offer mouse, rat, rabbit, rhesus macaque, and cynomolgus proteins for your experimental animal studies. Our stringent quality control standards guarantee purity greater than 95% and endotoxin level smaller than 0.1 ng/μg for every product.